[go: up one dir, main page]

MX2019007377A - Uso de inhibidores de la quimasa para el tratamiento de la endometriosis, la fibrosis postoperatoria y los trastornos que se caracterizan por fibrosis. - Google Patents

Uso de inhibidores de la quimasa para el tratamiento de la endometriosis, la fibrosis postoperatoria y los trastornos que se caracterizan por fibrosis.

Info

Publication number
MX2019007377A
MX2019007377A MX2019007377A MX2019007377A MX2019007377A MX 2019007377 A MX2019007377 A MX 2019007377A MX 2019007377 A MX2019007377 A MX 2019007377A MX 2019007377 A MX2019007377 A MX 2019007377A MX 2019007377 A MX2019007377 A MX 2019007377A
Authority
MX
Mexico
Prior art keywords
fibrosis
treatment
endometriosis
post
diseases
Prior art date
Application number
MX2019007377A
Other languages
English (en)
Inventor
Peters Michaele
Koch Markus
Zollner Thomas
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MX2019007377A publication Critical patent/MX2019007377A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente solicitud se relaciona con el uso de derivados de uracilo sustituido con bicíclicos, solos o en combinaciones con otros ingredientes activos para el tratamiento y/o la profilaxis de enfermedades, en particular para el tratamiento y/o profilaxis de trastornos inflamatorios y fibróticos, para el tratamiento de la endometriosis, de la fibrosis asociada a la endometriosis, de la adenomiosis y del dolor asociado con un trastorno de la endometriosis y también de la fibrosis peritoneal postoperatoria y la formación de adherencias.
MX2019007377A 2016-12-20 2017-12-13 Uso de inhibidores de la quimasa para el tratamiento de la endometriosis, la fibrosis postoperatoria y los trastornos que se caracterizan por fibrosis. MX2019007377A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16205339.1A EP3338780A1 (de) 2016-12-20 2016-12-20 Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind
PCT/EP2017/082569 WO2018114514A1 (de) 2016-12-20 2017-12-13 Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind

Publications (1)

Publication Number Publication Date
MX2019007377A true MX2019007377A (es) 2019-09-18

Family

ID=57570813

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007377A MX2019007377A (es) 2016-12-20 2017-12-13 Uso de inhibidores de la quimasa para el tratamiento de la endometriosis, la fibrosis postoperatoria y los trastornos que se caracterizan por fibrosis.

Country Status (19)

Country Link
US (1) US11266646B2 (es)
EP (2) EP3338780A1 (es)
JP (1) JP2020502272A (es)
KR (1) KR20190098984A (es)
CN (1) CN110072527A (es)
AU (1) AU2017381324A1 (es)
BR (1) BR112019012503A2 (es)
CA (1) CA3047448A1 (es)
CL (1) CL2019001713A1 (es)
EA (1) EA201991292A1 (es)
IL (1) IL266823B (es)
JO (1) JOP20190149A1 (es)
MA (1) MA47067A (es)
MX (1) MX2019007377A (es)
PH (1) PH12019501409A1 (es)
SG (1) SG10202106586TA (es)
TW (1) TWI753070B (es)
UA (1) UA124848C2 (es)
WO (1) WO2018114514A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021000933A1 (zh) * 2019-07-03 2021-01-07 南京明德新药研发有限公司 作为糜酶抑制剂的嘧啶酮类化合物及其应用
CN114671878B (zh) * 2020-12-25 2023-08-04 广东东阳光药业有限公司 取代的含氮双环化合物及其用途
CN114671856B (zh) * 2020-12-25 2023-10-20 广东东阳光药业股份有限公司 多取代的尿嘧啶衍生物及其用途
WO2025182946A1 (ja) * 2024-02-27 2025-09-04 東レ株式会社 肥満細胞が病態を増悪させる疾患の治療及び／又は予防用医薬組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062292A1 (en) * 2000-02-22 2001-08-30 Suntory Limited Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient
US7071220B2 (en) * 2000-09-18 2006-07-04 Toa Eiyo Ltd. N-substituted benzothiophenesulfonamide derivatives
US20040018984A1 (en) * 2002-07-17 2004-01-29 Mizuo Miyazaki Methods for preventing adhesion formation using protease inhibitors
EP2074121B1 (en) 2006-10-06 2016-11-30 Boehringer Ingelheim International GmbH Chymase inhibitors
JP5268120B2 (ja) * 2007-05-22 2013-08-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンゾイミダゾロンキマーゼ阻害薬
SG181883A1 (en) * 2009-12-25 2012-08-30 Daiichi Sankyo Co Ltd Seven-membered ring compound and pharmaceutical use therefor
UA112897C2 (uk) 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
AU2014345599B2 (en) 2013-11-08 2019-02-14 Bayer Pharma Aktiengesellschaft Salts of 1-(3-Methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1R)- 4-(trifluormethyl)-2,3-dihydro-1H-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carboxylic acid
CA2929762A1 (en) 2013-11-08 2015-05-14 Bayer Pharma Aktiengesellschaft Substituted 1,2,4-triazine-3,5-diones and the use thereof as chymase inhibitors
JP2016536362A (ja) 2013-11-08 2016-11-24 バイエル ファーマ アクチエンゲゼルシャフト 置換されているウラシル類及びそれらの使用
CN105873919A (zh) 2013-11-08 2016-08-17 拜耳医药股份有限公司 作为类糜蛋白酶抑制剂的取代的尿嘧啶

Also Published As

Publication number Publication date
MA47067A (fr) 2019-10-30
US20190381040A1 (en) 2019-12-19
JOP20190149A1 (ar) 2019-06-19
KR20190098984A (ko) 2019-08-23
EA201991292A1 (ru) 2019-12-30
TW201827053A (zh) 2018-08-01
BR112019012503A2 (pt) 2020-04-14
UA124848C2 (uk) 2021-12-01
IL266823A (en) 2019-07-31
WO2018114514A1 (de) 2018-06-28
JP2020502272A (ja) 2020-01-23
CN110072527A (zh) 2019-07-30
US11266646B2 (en) 2022-03-08
SG10202106586TA (en) 2021-07-29
IL266823B (en) 2022-03-01
EP3558316A1 (de) 2019-10-30
CA3047448A1 (en) 2018-06-28
EP3338780A1 (de) 2018-06-27
TWI753070B (zh) 2022-01-21
PH12019501409A1 (en) 2020-03-09
CL2019001713A1 (es) 2019-11-15
AU2017381324A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
PH12018500086A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
EP4272821A3 (en) Treatment of inflammatory diseases with inhibitors of c5a activity
PH12019501409A1 (en) Use of chymase inhibitors for the treatment of endometriosis, post-operative fibrosis and diseases which are characterized by fibrosis formation
MX2020003425A (es) Tratamiento de trastornos inflamatorios.
NZ736665A (en) Heterocyclic amides as kinase inhibitors
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
LT3472153T (lt) Pirimidin-2-ilamino-1h-pirazolai kaip lrrk2 inhibitoriai, skirti naudoti neurodegeneracinių sutrikimų gydyme
EP4378536A3 (en) Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
PH12016500862A1 (en) Autotaxin inhibitor compounds
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
PH12018500586B1 (en) Farnesoid x receptor agonists and uses thereof
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
EP4335512A3 (en) Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
WO2015168532A3 (en) Compositions and methods for modulating pkk expression
MX2020006587A (es) Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa.
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
EA201790802A1 (ru) Соединения против tnf
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
HK1217650A1 (zh) 用於治疗剧痛的组合物及方法
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
NZ713080A (en) Pyridin-4-yl derivatives
MX2015017035A (es) Inhibidor de la señalizacion de cd40 y un compuesto adicional, en donde el compuesto adicional es un acido labil, un derivado de acido labil, un agonista del receptor tgr5, un agonista del fxr o una combinacion de los mismos, para el tratamiento de inflamacion cronica, y la prevencion de cancer gastrointestinal o fibrosis.
EA201892714A1 (ru) Имидазолиновые соединения в качестве ингибиторов эластазы нейтрофилов человека
EA201791294A1 (ru) 7-(МОРФОЛИНИЛ)-2-(N-ПИПЕРАЗИНИЛ)МЕТИЛТИЕНО[2,3-c]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ
GB201519258D0 (en) Newly identified wnt/beta-catenin signal transduction inhibitors and the use thereof in the treatment or prevention of diseases and conditions.